Real-World Evidence
We have access to broad range of biospecimens
- Solid tumor blocks, plasma & peripheral blood
- NSCLC, SCLC, RCC, CRC, Breast Cancer etc.
- Archival and prospective collections
- Characterized via Pathology and Molecular analysis
- HE & IHC stained digital pathology images
- Whole exome sequencing, NGS targeted panel
- We have access to broad range of biospecimens
- Solid tumor blocks, plasma & peripheral blood
- NSCLC, SCLC, RCC, CRC, Breast Cancer etc.
- Archival and prospective collections
- Characterized via Pathology and Molecular analysis
- HE & IHC stained digital pathology images
- Whole exome sequencing, NGS targeted panel
- Solid tumor blocks, plasma & peripheral blood
Predict TMB Status From H&E-Stained Tissue Slides for NSCLC Adenocarcinoma
Bio-AI Data Lake
We use real world evidence data to enrich our algorithms to provide more robust solutions and predictive models to our clients and partners
Differentiators
Bio-AI’s novel AI platform and capabilities are well aligned with Biopharma Translational Medicine programs, clinical trial assays & companion diagnostic programs
Bio-AI offers “Bio DL Visualizer” a unique quality control tool that enables Pathologists to make rapid QC of how AI black box algorithms are performing
We have a design and development strategy for our robust prototype TMB module to further enable clinical study and diagnostic applications.
Bio-AI’s ML models can be expanded into additional indications and biomarkers that can help predict patient response to therapy, drug resistance & MOA
We have the capability to develop machine learning models on multi-omic data that can help predict patient response to therapy & drug resistance
Bio-AI has developed alliances with multiple biobanks across US, EU, Eastern EU and Asia. We offer our Biopharma clients access to rare indications, characterized biospecimens that have been profiled and characterized.
Differentiators
Bio-AI has developed alliances with multiple biobanks across the US, Europe, Eastern Europe, and Asia. Our aim is to provide our Pharma clients access to a broad range of patient tissue specimens for rare tumor indications, biomarkers, and specific characterized molecular profiles.